Dang Zhao, Jung Kathy, Qian Keduo, Lee Kuo-Hsiung, Huang Li, Chen Chin-Ho
Surgical Science, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, United States.
ACS Med Chem Lett. 2012;3(11):925-930. doi: 10.1021/ml3001962. Epub 2012 Aug 15.
Accumulation of aberrant protein aggregates, such as amyloid beta peptide (Aβ), due to decreased proteasome activities might contribute to the neurodegeneration in Alzheimer's disease. In this study, lithocholic acid derivatives 3α-O-pimeloyl-lithocholic acid methyl ester (2) and its isosteric isomer (6) were found to activate the chymotrypsin-like activity of the proteasome at an EC(50) of 7.8 and 4.3 μM, respectively. Replacing the C24 methyl ester in 2 with methylamide resulted in a complete devoid of proteasome activating activity. Epimerizing the C3 substituent from an alpha to beta orientation transformed the activator into a proteasome inhibitor. Unlike the cellular proteasome activator PA28, proteasome activated by 2 was not inhibited by Aβ. Furthermore, 2 potently antagonized the inhibitory effect of Aβ on the proteasome. In summary, compound 2 represents a novel class of small molecules that not only activates the proteasome but also antagonizes the inhibitory effect of Aβ on the proteasome.
蛋白酶体活性降低导致异常蛋白质聚集体(如β淀粉样肽(Aβ))的积累,可能是阿尔茨海默病神经退行性变的原因之一。在本研究中,发现石胆酸衍生物3α - O - 庚二酰 - 石胆酸甲酯(2)及其等排异构体(6)能激活蛋白酶体的类胰凝乳蛋白酶活性,其半数有效浓度(EC50)分别为7.8 μM和4.3 μM。将2中的C24甲酯替换为甲酰胺会导致其完全丧失蛋白酶体激活活性。将C3取代基从α构型差向异构化为β构型会使激活剂转变为蛋白酶体抑制剂。与细胞蛋白酶体激活剂PA28不同,由2激活的蛋白酶体不受Aβ抑制。此外,2能有效拮抗Aβ对蛋白酶体的抑制作用。总之,化合物2代表了一类新型小分子,它不仅能激活蛋白酶体,还能拮抗Aβ对蛋白酶体的抑制作用。